Safeguarding Every R&D Sample: How Sustainable Storage and Smart Scalability Keep Research Viable
This is an abridged version of a longer article originally published in Chemistry Today. Read the full publication here: Chemistry Today VOL. 43 (5) – September/October 2025 | Quality and Supply Chain Security
ABSTRACT
This article examines the critical importance of sustainable and scalable sample storage in safeguarding R&D samples for pharmaceutical, biotech, and CDMO organizations. It highlights how overlooked storage risks — from outdated infrastructure to regulatory gaps and transport failures — can compromise sample viability, delay research timelines, and drive up costs. The article aims to show that integrated sample stability and biorepository management should be proactive, requiring robust systems, smart cold chain logistics, disaster recovery planning, and clear data traceability. By reassessing internal capabilities and strategically outsourcing when appropriate, companies can protect their research investments and ensure continued innovation and compliance.
Introduction
Modern R&D organizations, from global pharmaceutical giants to specialized biotech and CDMOs, invest vast time, talent, and capital in developing breakthrough drugs, cell and gene therapies, vaccines, and new ingredients. But every promising asset, from a biological sample to a finished stability batch, is only as valuable as its integrity and viability.
Behind every vial, slide, or test batch lies a critical truth: storage is not passive. If a sample fails while in storage, the research timeline fails with it. It is easy to focus on the volume of material archived — thousands to millions of samples stored across global networks — while overlooking whether each unit is genuinely protected, tracked, and accessible when needed.
The Hidden Risks in R&D Storage
At its core, sample storage must preserve viability, not just maintain presence. Many companies learn this lesson the hard way: freezers age, power supplies falter, temperature alarms go unnoticed. Even robust systems can fail if staff assume a “set-and-forget” mentality.
A worrying industry statistic highlights the scale of the challenge: 4% of pharma shipments experience temperature excursions, and 1 in 10 pharmaceutical shipments sustains damage during transit. This means a significant fraction of stored or transported samples may fail quality checks when they reach the bench. The costs are not limited to wasted batches; they include hours of duplicated lab work, lost patient samples, delayed approvals, and reputational damage if studies fail inspections.
Regulatory Complexity: Getting Storage Right Globally
One of the biggest drivers of storage risk is regulatory diversity. Any company storing samples for clinical or commercial use must comply with overlapping international sample storage compliance standards: International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Q1A, ICH Q1B and ICH Q5C (stability testing), International Organization for Standardization (ISO) quality management standards, current good manufacturing practices (cGMP) and region-specific guidelines. Requirements often vary by product class — biologics, small molecules, vaccines — and by intended use.
In practical terms, this means an R&D director or operations team must ensure each sample storage equipment validation procedure meets regulatory compliance standards and the condition of samples in storage are validated for their full lifespan, sometimes years. This includes verifying backup power systems, ensuring humidity control is appropriate for local climate conditions, and maintaining complete, inspection-ready records of environmental monitoring.
The US Food and Drug Administration (FDA)-adopted ICH guidelines reinforce these expectations: ICH Q1A(R2) for small molecule stability and ICH Q5C for biologics. Both require stability studies to be conducted under qualified, validated, and continuously monitored storage conditions to ensure integrity across the sample lifecycle. Both guidelines, together with GMP requirements, also highlight the importance of contingency systems to protect against temperature excursions caused by power failures or equipment malfunctions. The importance of robust storage infrastructure is further underscored by FDA inspection data: in 2023, equipment-related issues (Subpart D) accounted for approximately 16.4% of all Form 483 observations. While facilities-related issues (Subpart B) made up 12.7%, illustrating how gaps in equipment validation, service, or environmental controls remain leading causes of regulatory non-compliance.
The Cold Chain and Transport Challenge
But storage is only half the story — the other half is transport. For many companies, the same samples that sit stable in ultra-low freezers must move globally between clinical sites, testing labs, or manufacturing partners. Every shipment adds risk: poor packaging, delays at customs, or temperature excursions in transit can undo months of carefully controlled storage.
Cold chain logistics alone can account for up to 20% of a pharmaceutical company’s total supply chain costs, according to Grand View Research. As product portfolios expand, with more biologics, personalized medicines, and global clinical trials, logistics teams quickly reach capacity managing multiple couriers, temperature ranges, and chain-of-custody requirements.
Disaster Recovery: The Cost of Not Planning
What happens if a storage freezer fails overnight? Or if a facility faces an unexpected power outage or flood? These are not rare hypotheticals; they are day-to-day realities. The truth is that most disruptions are internal, not caused by dramatic natural disasters. A stuck generator, a tripped alarm, or a backup system that is not serviced can trigger a chain reaction.
High-profile recalls underscore the risks of poor temperature control. For example, in 2021 cold chain lapses triggered insulin recalls when finished samples were stored below freezing, damaging both the formulation and the delivery. Similarly, in April 2025, a nationwide recall of a specific lot of the top-selling GLP-1 agonist (semaglutide) for weight management occurred after cartons were distributed without proper refrigeration, putting patients at risk due to compromised potency. While these specific recalls involve storage of the final product, the same temperature controls are critical during production: in-process bulk solutions, intermediates, or stability samples all depend on precise storage conditions. A lapse at this stage can degrade product quality long before distribution, demonstrating how overlooked temperature controls directly threaten drug integrity and patient safety.
Data is Part of Viability
Storing a sample is only the start; proving its integrity requires reliable data. When audits come, inspectors expect documented proof that conditions were within spec, that consent forms were valid, and that chain-of-custody records are traceable.
How to Scale Sustainably and When to Outsource
When R&D pipelines are small, internal storage often makes sense: it keeps teams close to samples and allows quick access. But as companies grow (expanding study numbers, adding sites, or partnering with multiple CROs and CDMOs), the scale of the challenge changes. New products might need unique storage conditions. Old infrastructure may not flex easily. Real estate or utility limits can become real bottlenecks.
It is no surprise that globally nearly 50% of R&D services are now outsourced, with outsourced cold chain and storage logistics partners representing a fast-growing share of the sample storage market. Many companies choose hybrid approaches: some samples stay in-house; others move to validated off-site capacity with experts focused only on storage quality and continuity.
Conclusion
Every sample represents more than material. It represents time, patient trust, and the future of innovation. Companies that treat storage and logistics as afterthoughts risk undermining their own progress. By planning for sustainability, scalability, and resilience now — and by using data and trusted partners, such as Astoriom, wisely — organizations can protect research investments and maintain their path to discovery.
Get in touch with our expert team to discuss your business needs.
